Clinical Trial Update: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of the FOLFIRINOX regimen in unresectable locally advanced and borderline resectable pancreatic cancer was terminated, with results posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-08-21